Department of Hepatobiliary Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, 277 Yanta West Road, Xi'an, 710061, China.
Department of Hepatobiliary Surgery, Zhejiang Provincial People's Hospital (People's Hospital of Hangzhou Medical College), Hangzhou, Zhejiang, 310014, China.
J Exp Clin Cancer Res. 2018 Mar 6;37(1):49. doi: 10.1186/s13046-018-0717-3.
Accumulating evidence confirm that aberrant microRNAs (miRNAs) expression contributes to hepatocellular carcinoma (HCC) development and progression. Previous study reported that miR-1468 showed an up-regulated tendency and might be a potential prognostic biomarker in HCC samples derived from TCGA database. However, the role of miR-1468 and its underlying mechanisms involved in the growth and metastasis of HCC remain poorly investigated.
CCK-8, EdU, colony formation and flow cytometry were used to determine proliferation, cell cycle progression and apoptosis of HCC cells in vitro. The subcutaneous tumor model in nude mice was established to detect tumor growth of HCC in vivo. The direct binding of miR-1468 to 3'UTR of Cbp/p300 interacting transactivator with Glu/Asp rich carboxy-terminal domain 2 (CITED2) and Up-frameshift protein 1 (UPF1) was confirmed by luciferase reporter assay.
Here, we demonstrated that miR-1468 expression was up-regulated in HCC tissues and cell lines. Clinical analysis revealed that increased miR-1468 level was significantly correlated with malignant prognostic features and shorter survival. Gain- and loss-of-function experiments indicated that miR-1468 promoted cell proliferation, colony formation, cell cycle progression and induced apoptosis of HCC cells in vitro and in vivo. Moreover, CITED2 and UPF1 were identified as direct downstream targets of miR-1468 in HCC cells, and mediated the functional effects of miR-1468 in HCC, resulting in peroxisome proliferator-activated receptor-γ (PPAR-γ)/AKT signaling activation. In clinical samples of HCC, miR-1468 inversely correlated with the levels of CITED2 and UPF1, which were confirmed to be down-regulated in HCC. Restoration of CITED2 or UPF1 expression at least partially abolished the biological effects of miR-1468 on HCC cells. Moreover, alteration of PPAR-γ or AKT phosphorylation could reverse the function of miR-1468 in HCC.
Taken together, this research supports the first evidence that miR-1468 plays an oncogenic role in HCC via activating PPAR-γ/AKT pathway by targeting CITED2 and UPF1, and represents a promising therapeutic strategy for HCC patients.
越来越多的证据证实,异常表达的 microRNAs(miRNAs)参与了肝细胞癌(HCC)的发生和发展。先前的研究表明,miR-1468 在 TCGA 数据库来源的 HCC 样本中呈现上调趋势,可能是一种潜在的预后生物标志物。然而,miR-1468 在 HCC 生长和转移中的作用及其潜在机制仍未得到充分研究。
使用 CCK-8、EdU、集落形成和流式细胞术来确定 HCC 细胞在体外的增殖、细胞周期进程和细胞凋亡。建立裸鼠皮下肿瘤模型来检测 HCC 在体内的肿瘤生长。通过荧光素酶报告实验证实 miR-1468 与 Cbp/p300 相互作用的转录激活因子与 Glu/Asp 丰富的羧基末端域 2(CITED2)和 Up-frameshift 蛋白 1(UPF1)的 3'UTR 的直接结合。
本研究表明,miR-1468 在 HCC 组织和细胞系中表达上调。临床分析显示,miR-1468 水平升高与恶性预后特征和生存期缩短显著相关。增益和缺失功能实验表明,miR-1468 促进 HCC 细胞在体外和体内的增殖、集落形成、细胞周期进程和诱导细胞凋亡。此外,CITED2 和 UPF1 被鉴定为 HCC 细胞中 miR-1468 的直接下游靶标,并介导了 miR-1468 在 HCC 中的功能效应,导致过氧化物酶体增殖物激活受体-γ(PPAR-γ)/AKT 信号激活。在 HCC 的临床样本中,miR-1468 与 CITED2 和 UPF1 的水平呈负相关,这两种蛋白在 HCC 中被证实下调。CITED2 或 UPF1 的表达恢复至少部分消除了 miR-1468 对 HCC 细胞的生物学效应。此外,改变 PPAR-γ 或 AKT 磷酸化可以逆转 miR-1468 在 HCC 中的功能。
综上所述,本研究首次证明,miR-1468 通过靶向 CITED2 和 UPF1 激活 PPAR-γ/AKT 通路在 HCC 中发挥致癌作用,为 HCC 患者提供了一种有前途的治疗策略。